A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis - Sorbonne Université
Journal Articles Arthritis & rheumatology Year : 2019

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Roy Fleischmann
Henning Bliddal
  • Function : Author
Francisco Blanco
Thomas Schnitzer
  • Function : Author
Charles Peterfy
  • Function : Author
Su Chen
  • Function : Author
Li Wang
  • Function : Author
Sheng Feng
  • Function : Author
Philip Conaghan
  • Function : Author
Francis Berenbaum
Centre de Recherche Saint-Antoine
Jean‐pierre Pelletier
  • Function : Author
Johanne Martel-Pelletier
  • Function : Author
Ole Vaeterlein
  • Function : Author
Gurjit Kaeley
  • Function : Author
Wei Liu
  • Function : Author
Matthew Kosloski
  • Function : Author
Gwen Levy
  • Function : Author
Lanju Zhang
  • Function : Author
Jeroen Medema
  • Function : Author
Marc Levesque
  • Function : Author

Domains

Life Sciences [q-bio]

francis berenbaum  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03994418

Submitted on : Friday, February 17, 2023-2:52:58 PM

Last modification on : Thursday, December 14, 2023-1:50:38 PM

Consult the full text

Dates and versions

hal-03994418 , version 1 (17-02-2023)

Identifiers

Cite

Roy Fleischmann, Henning Bliddal, Francisco Blanco, Thomas Schnitzer, Charles Peterfy, et al.. A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis & rheumatology, 2019, 71 (7), pp.1056-1069. ⟨10.1002/art.40840⟩. ⟨hal-03994418⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

U938 SORBONNE-UNIVERSITE SU-MEDECINE
19 View
0 Download

Altmetric

Share

More